An observational study in ATTR Amyloidosis, sponsored by Fondazione IRCCS Policlinico San Matteo di Pavia. Recruiting at 30 sites in Italy. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-03-27.
Sponsored by Fondazione IRCCS Policlinico San Matteo di Pavia · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 52 studies in Amyloidosis with a site in Italy — 14 open to participants now, 17 under way, 7 of them phase 3. Amyloidosis · Italy.
Among the 52 studies in Amyloidosis with a site in Italy, this one is the 5th largest by planned enrollment of the 14 observational ones that give a count, is one of 6 that started in 2022, is one of 14 observational ones, reaches primary completion later than 3 of the 16 other live ones, and was the 37th registered.
290 studies on the registry are indexed under Amyloidosis; 92 are open to participants now.
Browse Amyloidosis studies →14 of the 52 studies in Amyloidosis with a site in Italy are open now. Recruiting first, the newest first:
Alnylam Pharmaceuticals · Sites in Italy, United States, Argentina and 19 more countries
Ages 18–85
Alnylam Pharmaceuticals · Sites in Italy, United States, Argentina and 33 more countries
Ages 18–85
Eidos Therapeutics, a BridgeBio company · Sites in Italy, United States, Argentina and 21 more countries
Ages 18–75
AbbVie · Sites in Italy, United States, Australia and 3 more countries
Ages 18+
Paolo Milani · Sites in Italy
Ages 18–99
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 70 Amyloidosis studies recruiting now, 43 (61%) set no upper age limit and 3 (4%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
52 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 12 · Phase 3 25
First in 2001; this study’s year is marked. 6 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,000 is above the median of 190 across 83 observational studies indexed under Amyloidosis.
Median enrollment 160 across the 38 interventional studies, 365 across the 14 observational. Of the 33 that completed or were terminated, 17 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 52 have an industry lead sponsor. The 10 most frequent:
Fondazione IRCCS Policlinico San Matteo di Pavia is the lead sponsor of 258 studies on the registry; 115 are open to participants now.
Fondazione IRCCS Policlinico San Matteo di Pavia has 8 studies filed under Amyloidosis — fewer than ten, so there is no comparison to draw.
3 of the studies in Amyloidosis with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05444920Fondazione IRCCS Policlinico San Matteo di PaviaThe Italian Transthyretin Amyloidosis Web-Network | 2026-12-31 |
| NCT06251778Paolo MilaniNatiOnal Referral cenTEr Study of Transthyretin Amyloid Cardiomyopathy(ATTR) Patients on Tafamidis | 2027-01-26 |
| NCT04839003Fondazione IRCCS Policlinico San Matteo di PaviaA Registry of AL Amyloidosis (ReAL) | 2027-05 |
Add all 3 to your calendar (.ics) → With an account.
Among the 52 studies in Amyloidosis with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study aims, by generating a large registry of patients with ATTR amyloidosis, including data at diagnosis and during follow up, to describe the natural history of ATTR amyloidosis in a real-world setting and to define and validate prognostic models, response criteria applicable at any point of the disease. The registry will also be used for data sharing and to allow the possibility of a close collaboration amongst the amyloidosis experts of the ARTC and all the physicians around the Country involved in the diagnosis and management of systemic amyloidosis. Thanks to the online registry, the diagnostic facility of the ARTC will be made available to requesting physicians.
Patients will be entered the database pending on expressing an informed consent of the use of their data for research purposes. Data of deceased patients will be used only if they have expressed their consent to the use of their clinical data
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
1. Diagnosis of light chain (AL) amyloidosis
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Establishing an online tool for data-sharing, available for health care providers
Different data (types type of organ involvement, biomarkers of organ damage, date of onset of symptoms, date of diagnosis, type of treatment (if any)) will be shared between the health-care professionals and the panel of experts.
Time frame: 5 years
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2022 (actual). Primary completion is estimated for Dec 2026, 53 months after the start.
Of 52 observational studies under Amyloidosis, half reached primary completion within 97 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 183. This study's planned 53 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fondazione IRCCS Policlinico San Matteo di Pavia →